ASC Investment ROI Calculator
You've been offered equity in an ambulatory surgery center. The buy-in is real money — $200K, $400K, sometimes more. What you get back in distributions over the next decade, and what your stake is worth when the ASC sells, is where ortho surgeons build serious wealth. Enter your actual numbers to model the full picture.
How to read these results
Net cash this year is your distribution minus your loan payment (if financed). Year 1 also deducts the cash portion of your buy-in — that's the capital you put in on day one.
Cumulative cash is the running total. When it turns positive, you've broken even on the investment from distributions alone — before any exit. Most well-structured ortho ASC investments break even on distributions within 2–5 years.
Exit proceeds are modeled as your final-year distribution × your exit multiple. This is a reasonable proxy because ASCs are generally valued on a multiple of distributable cash flow (EBITDA), and your share of distributions approximates your share of EBITDA. At exit, add the exit proceeds to your cumulative cash total for your full return.
IRR is the annualized return on invested capital across all cash flows, including exit. This is the number to compare against other investment opportunities — private equity funds, index funds, real estate, etc. Well-structured ortho ASC investments have historically produced IRRs in the 20–50%+ range when exit multiples are strong.
- After-tax distributions. ASC distributions on a K-1 are ordinary income at your marginal rate (37% federal for most ortho surgeons). Exit proceeds may be taxed as long-term capital gains (23.8% combined federal for high earners: 20% + 3.8% NIIT). The pre-tax vs after-tax gap matters enormously over a 10-year hold.
- QBI deduction eligibility. Whether your ASC interest qualifies for the Section 199A pass-through deduction depends on entity structure and your income level — worth $30–70K/yr in additional deduction for surgeons in the right structure.
- ASC valuation quality. The buy-in price you're offered reflects someone's valuation of the ASC. An independent analysis often reveals whether you're buying in at fair value, at a premium, or (rarely) at a discount. Orthopedic groups sometimes use new-surgeon buy-ins to recapitalize at above-market valuations.
- Federal Stark Law and Anti-Kickback safe harbors. Physician ownership in ASCs must qualify under specific regulatory safe harbors. Your interest percentage and ownership structure must comply — a specialist advisor who works with physicians knows these rules cold.
- What happens if you leave the group. Partnership agreements vary widely on forced buyouts, put/call provisions, and what you receive if you retire or move to hospital employment. Read the operating agreement before writing the check.
What makes a good ASC investment?
Not all ASC equity stakes are equal. Here's what experienced advisors look for:
- Payback period under 3 years. A buy-in that pays back purely from distributions within 3 years is strong. 3–5 years is solid. Over 5 years warrants scrutiny of case volume trends.
- Fair entry valuation. Orthopedic ASCs selling equity to new surgeons should be priced at a multiple consistent with their actual EBITDA. Verify this independently — groups have been known to mark up buy-in prices when adding a new partner.
- Case volume trajectory. Distributions grow with case volume. An ASC adding new service lines (robotics, spine, total joints) has a different growth profile than one running at capacity with no expansion planned.
- Payer mix. Commercial and self-pay cases generate 3–5× what Medicare cases do. A predominantly Medicare spine center will have different economics than a commercial-heavy sports medicine center.
- Strategic exit path. USPI, SurgCenter Development (now part of Tenet/USPI2), hospital systems, and private equity are all active acquirers. An ASC with no plausible exit path constrains your upside.
Related tools and guides
Have a specific ASC investment to evaluate?
A specialist advisor will review the operating agreement, validate the entry valuation, model after-tax returns, and flag anything that could cost you at exit. Free match, no obligation.
- FOCUS Investment Banking, Ambulatory Surgery Center EBITDA Multiples 2026 Report — single-specialty ASCs 5–8×, multi-specialty 6–10×, with landmark USPI/SurgCenter transaction at 10.8×. focusbankers.com
- Tenet Healthcare committed nearly $1.5B to acquire 92 SurgCenter ASCs in 2025–2026. Fierce Healthcare
Market figures verified April 2026. Exit multiples are estimates; actual transaction pricing varies by center size, case mix, payer mix, and acquirer. All calculator outputs are pre-tax gross figures.